A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
New technology allows scientists to dive into the inner world of cells in everything from cancers to mummies. Learn more at lab’s open house on July 10.
At Columbia, personalized medicine represents a commitment to harness the institution’s intellectual and technological resources to transform both medical research and patient care.